Hematoloxía
Servicio
University of Oslo
Oslo, NoruegaPublicacións en colaboración con investigadores/as de University of Oslo (3)
2021
2019
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107
-
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794